Copyright
©The Author(s) 2024.
World J Clin Oncol. Dec 24, 2024; 15(12): 1468-1480
Published online Dec 24, 2024. doi: 10.5306/wjco.v15.i12.1468
Published online Dec 24, 2024. doi: 10.5306/wjco.v15.i12.1468
Chemotherapy type | |
Cisplatin-based | 52 (48) |
Carboplatin-based | 50 (47) |
Cetuximab also | 66 (62) |
Other chemotherapy | 5 (5) |
Maintenance with cetuximab | |
Yes | 48 (45) |
No | 59 (55) |
Previous radiotherapy | |
Yes | 100 (94) |
No | 7 (6) |
Best response of maintenance | |
Complete response | 1 (1) |
Partial response | 28 (27) |
Stabilization of disease | 18 (16) |
Disease progression | 60 (56) |
- Citation: Fasano M, Pirozzi M, Vitale P, Damiano V, Ronzino G, Farese S, Carfora V, Ciccarelli G, Di Giovanni I, Facchini S, Cennamo G, Caraglia M, Ciardiello F, Addeo R. Paclitaxel for second-line treatment of squamous cell carcinoma of the head and neck: A multicenter retrospective Italian study. World J Clin Oncol 2024; 15(12): 1468-1480
- URL: https://www.wjgnet.com/2218-4333/full/v15/i12/1468.htm
- DOI: https://dx.doi.org/10.5306/wjco.v15.i12.1468